Ann W. Walsh

Clinical Emergence of Entecavir-Resistant Hepatitis B Virus Requires Additional Substitutions in Virus Already Resistant to Lamivudine

Daniel J. Tenney, Steven M. LeVine, R.E. Rose et al. · Antimicrobial Agents and Chemotherapy · 2004 · 537 citations · Full text

Vaccination, Clinical Emergence, Health Sciences +15

Entecavir resistance is rare in nucleoside naïve patients with hepatitis B

Richard J. Colonno, Ronald E. Rose, Carl J. Baldick et al. · Hepatology · 2006 · 347 citations · Full text

Diagnostic Virology, Hbv Replication, Hepatology +15

Two-Year Assessment of Entecavir Resistance in Lamivudine-Refractory Hepatitis B Virus Patients Reveals Different Clinical Outcomes Depending on the Resistance Substitutions Present

Daniel J. Tenney, Ronald E. Rose, Carl J. Baldick et al. · Antimicrobial Agents and Chemotherapy · 2006 · 239 citations · Full text

4-Thiazolidinones: novel inhibitors of the bacterial enzyme murB

Charles J. Andres, Joanne J. Bronson, Stanley V. D’Andrea et al. · Bioorganic & Medicinal Chemistry Letters · 2000 · 218 citations

Medicine, Bacterial Enzyme Murb, Antibacterial Agent +6

Inhibition of Hepatitis B Virus Polymerase by Entecavir

David R. Langley, Ann W. Walsh, Carl J. Baldick et al. · Journal of Virology · 2007 · 187 citations · Full text

Viral Replication, Biochemistry, Viral Hepatitis +15